Breslin advises shareholders, corporates and investors on strategic transactions where execution depends on more than generic corporate-finance coverage. We support sell-side M&A, divestments, carve-outs, buy-side mandates and strategic reviews across innovation-led, knowledge-intensive sectors — situations where technical depth, buyer education and tailored process design materially affect the outcome.
Our work concentrates on businesses and assets that cannot be marketed as commodities: venture-backed companies, healthcare and biotech platforms, industrial-technology positions, non-core corporate holdings and portfolio assets that need to be re-positioned before they reach a buyer. The mandates are often cross-border, frequently involve a small but precisely chosen buyer set, and reward sector fluency over sheer process volume.
• Sell-side M&A
• Divestments and exits
• Non-core asset disposals
• Carve-outs and strategic separations
• Buy-side advisory and target screening
• Portfolio rationalisation and strategic reviews
• Valuation framing, diligence support and negotiation coordination
• Independent advisory for boards and shareholders on transaction options
We run structured outreach across European, UK and US strategic and financial buyers — including pharma, medtech and industrial corporates, private equity, growth funds, family offices and selected institutional investors. Reach is targeted, not blanketed.
Auctions are not always the right answer. For some assets a tightly held competitive process maximises value; for others a single bilateral with the right partner does. We design the process around the asset, the timing and the shareholders’ actual objectives.
Breslin is independent. We have no balance-sheet products to sell and no conflicting commitments to a buyer-side franchise. Boards and shareholders engage us to give a clear view, a defensible recommendation and a clean process.
Life sciences, biotech, pharma, medtech, diagnostics and digital health; industrial biotech, agro/food, chemicals; energy transition and selected technology applications.
Strategic transactions in innovation-led sectors are won on preparation, narrative and buyer fit — not on auction theatre. Breslin combines decades of transaction execution with operational and scientific depth in the sectors we cover. Our team has supported sell-side, buy-side and divestment mandates across Europe and the US, including processes for global pharma and chemicals corporates, venture-backed biotechs and bank- and corporate-owned portfolios.
Strategic options review, perimeter definition, valuation framing, equity story and documentation readiness.
Targeted buyer universe across strategic and financial counterparties; confidential approach, NDA management and management presentations.
Data room coordination, expert sessions, offer analysis, structuring trade-offs and competitive tension management.
Term-sheet and SPA negotiation support, working with legal and tax counsel through to signing, escrow and completion.
Sale mandates and portfolio realignment work involving non-core biotech, medtech and cleantech assets.
Track record covering sourcing, financing and value realisation in biotechnology transaction contexts.
Exclusive strategic consultant on a combined financing, M&A and resulting in a successful M&A process.
Yes. We support full strategic processes for whole companies as well as narrower asset, project, pipeline or portfolio transactions.
Depending on the mandate: strategic corporates, private equity, growth equity, secondary funds, family offices, venture investors and selected institutional buyers.
Yes. Breslin is an independent advisory firm with no underwriting or buy-side balance-sheet exposure that could conflict with client interests.
Yes. We have supported target screening, opportunity evaluation and transaction development for selected buy-side assignments.
Secondaries focus on transferring fund or direct positions, often LP- or GP-led, where the seller is moving an investment. M&A and divestments focus on company-level or business-unit transactions where the underlying asset is operational. There is overlap on carve-outs and externalisation — Breslin uses whichever route fits the mandate, and many engagements draw on both teams.
Strategic Transaction and M&A Advisory
Discuss an M&A, divestment, carve-out or strategic-review mandate with Breslin.
